Skip to main content
Top
Published in: Current Fungal Infection Reports 1/2013

01-03-2013 | Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Animal Models In Mycology: What Have We Learned Over The Past 30 Years

Authors: William R. Kirkpatrick, Nathan P. Wiederhold, Laura K. Najvar, Thomas F. Patterson

Published in: Current Fungal Infection Reports | Issue 1/2013

Login to get access

Abstract

Animal models have long been used to explore various pathophysiological, immunological and microbiological questions in the field of medical mycology. These models have been adapted and altered over time, yet their use has persisted. They remain valuable as research tools due to similarities to processes in human physiology and disease, and are evolving to include more fungal pathogens and infections that better mimic disease in humans. Animal availability, animal cost, housing requirements, the need for immunosuppression, the potential for tissue, fluid or blood samples, a researcher’s familiarity with the model, as well as governmental or institutional regulations, must all be considered when selecting an appropriate one to use. Although the questions of interest have changed over the past 30 years, one idea persists: animal models are valuable tools in research that span the gap between the bench and the clinic.
Literature
1.
go back to reference • Capilla J, Clemons KV, Stevens DA. Animal models: an important tool in mycology. Med Mycol. 2007;45:657–84. A comprehensive review of animal models of invasive fungal infections.PubMedCrossRef • Capilla J, Clemons KV, Stevens DA. Animal models: an important tool in mycology. Med Mycol. 2007;45:657–84. A comprehensive review of animal models of invasive fungal infections.PubMedCrossRef
2.
go back to reference Szabo EK, MacCallum DM. The contribution of mouse models to our understanding of systemic candidiasis. FEMS Microbiol Lett. 2011;320:1–8.PubMedCrossRef Szabo EK, MacCallum DM. The contribution of mouse models to our understanding of systemic candidiasis. FEMS Microbiol Lett. 2011;320:1–8.PubMedCrossRef
3.
go back to reference Naglik JR, Fidel Jr PL, Odds FC. Animal models of mucosal Candida infection. FEMS Microbiol Lett. 2008;283:129–39.PubMedCrossRef Naglik JR, Fidel Jr PL, Odds FC. Animal models of mucosal Candida infection. FEMS Microbiol Lett. 2008;283:129–39.PubMedCrossRef
4.
go back to reference Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531–40.PubMedCrossRef Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531–40.PubMedCrossRef
5.
go back to reference Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–66.PubMedCrossRef Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–66.PubMedCrossRef
6.
go back to reference Dixon DM, Polak A, Walsh TJ. Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice. Infect Immun. 1989;57:1452–6.PubMed Dixon DM, Polak A, Walsh TJ. Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice. Infect Immun. 1989;57:1452–6.PubMed
7.
go back to reference Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362:1828–38.PubMedCrossRef Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362:1828–38.PubMedCrossRef
8.
go back to reference Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Med Mycol. 2009;47 Suppl 1:S271–81.PubMedCrossRef Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Med Mycol. 2009;47 Suppl 1:S271–81.PubMedCrossRef
9.
go back to reference Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology. 1994;140(Pt 9):2475–9.PubMedCrossRef Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology. 1994;140(Pt 9):2475–9.PubMedCrossRef
10.
go back to reference •• Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun. 2005;73:494–503. Study comparing the pathogenesis of invasive pulmonary aspergillosis in neutropenic mice versus those who were immunosuppressed with corticosteroids alone.PubMedCrossRef •• Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun. 2005;73:494–503. Study comparing the pathogenesis of invasive pulmonary aspergillosis in neutropenic mice versus those who were immunosuppressed with corticosteroids alone.PubMedCrossRef
11.
go back to reference • Spikes S, Xu R, Nguyen CK, et al. Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis. 2008;197:479–86. Study demonstrating differences in virulence for the mycotoxin gliotoxin between neutropenic and non-neutropenic immunosuppressed mice.PubMedCrossRef • Spikes S, Xu R, Nguyen CK, et al. Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis. 2008;197:479–86. Study demonstrating differences in virulence for the mycotoxin gliotoxin between neutropenic and non-neutropenic immunosuppressed mice.PubMedCrossRef
12.
go back to reference Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother. 2000;44:780–2.PubMedCrossRef Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother. 2000;44:780–2.PubMedCrossRef
13.
go back to reference Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of posaconazole in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother. 2000;44:780–2.PubMedCrossRef Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of posaconazole in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother. 2000;44:780–2.PubMedCrossRef
14.
go back to reference Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother. 2000;44:2865–8.PubMedCrossRef Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother. 2000;44:2865–8.PubMedCrossRef
15.
go back to reference Mavridou E, Bruggemann RJ, Melchers WJ, et al. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother. 2010;54:860–5.PubMedCrossRef Mavridou E, Bruggemann RJ, Melchers WJ, et al. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother. 2010;54:860–5.PubMedCrossRef
16.
go back to reference Mavridou E, Bruggemann RJ, Melchers WJ, et al. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 2010;54:4758–64.PubMedCrossRef Mavridou E, Bruggemann RJ, Melchers WJ, et al. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 2010;54:4758–64.PubMedCrossRef
17.
go back to reference Lewis RE, Wiederhold NP. Murine model of invasive aspergillosis. Methods Mol Med. 2005;118:129–42.PubMed Lewis RE, Wiederhold NP. Murine model of invasive aspergillosis. Methods Mol Med. 2005;118:129–42.PubMed
18.
go back to reference Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004;190:1464–71.PubMedCrossRef Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004;190:1464–71.PubMedCrossRef
19.
go back to reference •• Sheppard DC, Rieg G, Chiang LY, et al. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2004;48:1908–11. First study to report the use of a nebulizer and an acrylic chamber for the aerosolization of Aspergillus conidia in order to establish invasive pulmonary aspergillosis in mice.PubMedCrossRef •• Sheppard DC, Rieg G, Chiang LY, et al. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2004;48:1908–11. First study to report the use of a nebulizer and an acrylic chamber for the aerosolization of Aspergillus conidia in order to establish invasive pulmonary aspergillosis in mice.PubMedCrossRef
20.
go back to reference Sheppard DC, Graybill JR, Najvar LK, et al. Standardization of an experimental murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006;50:3501–3.PubMedCrossRef Sheppard DC, Graybill JR, Najvar LK, et al. Standardization of an experimental murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006;50:3501–3.PubMedCrossRef
21.
go back to reference Vallor AC, Kirkpatrick WR, Najvar LK, et al. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob Agents Chemother. 2008;52:2593–8.PubMedCrossRef Vallor AC, Kirkpatrick WR, Najvar LK, et al. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob Agents Chemother. 2008;52:2593–8.PubMedCrossRef
22.
go back to reference Wiederhold NP, Thornton CR, Najvar LK, et al. Comparison of lateral flow technology and galactomannan and (1->3)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis. Clin Vaccine Immunol. 2009;16:1844–6.PubMedCrossRef Wiederhold NP, Thornton CR, Najvar LK, et al. Comparison of lateral flow technology and galactomannan and (1->3)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis. Clin Vaccine Immunol. 2009;16:1844–6.PubMedCrossRef
23.
go back to reference Lengerova M, Kocmanova I, Racil Z, et al. Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-beta-D-glucan detection. J Clin Microbiol. 2012;50:602–8.PubMedCrossRef Lengerova M, Kocmanova I, Racil Z, et al. Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-beta-D-glucan detection. J Clin Microbiol. 2012;50:602–8.PubMedCrossRef
24.
go back to reference Dufresne SF, Datta K, Li X, et al. Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis. PLoS One. 2012;7:e42736.PubMedCrossRef Dufresne SF, Datta K, Li X, et al. Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis. PLoS One. 2012;7:e42736.PubMedCrossRef
25.
go back to reference Petraitis V, Petraitiene R, Hope WW, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother. 2009;53:2382–91.PubMedCrossRef Petraitis V, Petraitiene R, Hope WW, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother. 2009;53:2382–91.PubMedCrossRef
26.
go back to reference Hope WW, Petraitis V, Petraitiene R, et al. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) beta-d-glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother. 2010;54:4879–86.PubMedCrossRef Hope WW, Petraitis V, Petraitiene R, et al. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) beta-d-glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother. 2010;54:4879–86.PubMedCrossRef
27.
go back to reference Walsh TJ, Garrett K, Feuerstein E, et al. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother. 1995;39:1065–9.PubMedCrossRef Walsh TJ, Garrett K, Feuerstein E, et al. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother. 1995;39:1065–9.PubMedCrossRef
28.
go back to reference Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother. 2001;45:857–69.PubMedCrossRef Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother. 2001;45:857–69.PubMedCrossRef
29.
go back to reference Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother. 2002;46:12–23.PubMedCrossRef Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother. 2002;46:12–23.PubMedCrossRef
30.
go back to reference Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2002;46:1857–69.PubMedCrossRef Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2002;46:1857–69.PubMedCrossRef
31.
go back to reference Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses. 2007;50:227–31.PubMedCrossRef Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses. 2007;50:227–31.PubMedCrossRef
32.
go back to reference Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–97.PubMedCrossRef Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–97.PubMedCrossRef
33.
go back to reference Lozano-Chiu M, Arikan S, Paetznick VL, et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother. 1999;43:589–91.PubMedCrossRef Lozano-Chiu M, Arikan S, Paetznick VL, et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother. 1999;43:589–91.PubMedCrossRef
34.
go back to reference Wiederhold NP, Najvar LK, Bocanegra R, et al. Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. Antimicrob Agents Chemother. 2010;54:1055–9.PubMedCrossRef Wiederhold NP, Najvar LK, Bocanegra R, et al. Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. Antimicrob Agents Chemother. 2010;54:1055–9.PubMedCrossRef
35.
go back to reference Ruiz-Cendoya M, Marine M, Guarro J. Combined therapy in treatment of murine infection by Fusarium solani. J Antimicrob Chemother. 2008;62:543–6.PubMedCrossRef Ruiz-Cendoya M, Marine M, Guarro J. Combined therapy in treatment of murine infection by Fusarium solani. J Antimicrob Chemother. 2008;62:543–6.PubMedCrossRef
36.
go back to reference Spellberg B, Schwartz J, Fu Y, et al. Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother. 2006;58:973–9.PubMedCrossRef Spellberg B, Schwartz J, Fu Y, et al. Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother. 2006;58:973–9.PubMedCrossRef
37.
go back to reference Capilla J, Mayayo E, Serena C, et al. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B. J Antimicrob Chemother. 2004;54:1092–5.PubMedCrossRef Capilla J, Mayayo E, Serena C, et al. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B. J Antimicrob Chemother. 2004;54:1092–5.PubMedCrossRef
38.
go back to reference Rodriguez MM, Calvo E, Serena C, et al. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53:2153–5.PubMedCrossRef Rodriguez MM, Calvo E, Serena C, et al. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53:2153–5.PubMedCrossRef
39.
go back to reference Rodriguez MM, Pastor FJ, Salas V, et al. Experimental murine scedosporiosis: histopathology and azole treatment. Antimicrob Agents Chemother. 2010;54:3980–4.PubMedCrossRef Rodriguez MM, Pastor FJ, Salas V, et al. Experimental murine scedosporiosis: histopathology and azole treatment. Antimicrob Agents Chemother. 2010;54:3980–4.PubMedCrossRef
40.
go back to reference Gonzalez GM, Tijerina R, Najvar LK, et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother. 2003;47:1436–8.PubMedCrossRef Gonzalez GM, Tijerina R, Najvar LK, et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother. 2003;47:1436–8.PubMedCrossRef
41.
go back to reference Harun A, Serena C, Gilgado F, et al. Scedosporium aurantiacum is as virulent as S. prolificans, and shows strain-specific virulence differences, in a mouse model. Med Mycol. 2010;48 Suppl 1:S45–51.PubMedCrossRef Harun A, Serena C, Gilgado F, et al. Scedosporium aurantiacum is as virulent as S. prolificans, and shows strain-specific virulence differences, in a mouse model. Med Mycol. 2010;48 Suppl 1:S45–51.PubMedCrossRef
42.
go back to reference Ibrahim AS, Avanessian V, Spellberg B, Edwards Jr JE. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother. 2003;47:3343–4.PubMedCrossRef Ibrahim AS, Avanessian V, Spellberg B, Edwards Jr JE. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother. 2003;47:3343–4.PubMedCrossRef
43.
go back to reference Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005;49:721–7.PubMedCrossRef Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005;49:721–7.PubMedCrossRef
44.
go back to reference Ibrahim AS, Edwards Jr JE, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006;58:1070–3.PubMedCrossRef Ibrahim AS, Edwards Jr JE, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006;58:1070–3.PubMedCrossRef
45.
go back to reference Rodriguez MM, Pastor FJ, Calvo E, et al. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother. 2009;53:5022–5.PubMedCrossRef Rodriguez MM, Pastor FJ, Calvo E, et al. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother. 2009;53:5022–5.PubMedCrossRef
46.
go back to reference Rodriguez MM, Pastor FJ, Sutton DA, et al. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother. 2010;54:1665–9.PubMedCrossRef Rodriguez MM, Pastor FJ, Sutton DA, et al. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother. 2010;54:1665–9.PubMedCrossRef
47.
go back to reference Rodriguez MM, Serena C, Marine M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52:3786–8.PubMedCrossRef Rodriguez MM, Serena C, Marine M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52:3786–8.PubMedCrossRef
48.
go back to reference Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649–57.PubMedCrossRef Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649–57.PubMedCrossRef
49.
go back to reference Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120:1914–24.PubMedCrossRef Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120:1914–24.PubMedCrossRef
50.
go back to reference Lewis RE, Albert ND, Liao G, et al. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother. 2010;54:1298–304.PubMedCrossRef Lewis RE, Albert ND, Liao G, et al. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother. 2010;54:1298–304.PubMedCrossRef
51.
go back to reference Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.PubMedCrossRef Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.PubMedCrossRef
52.
go back to reference Ibrahim AS, Gebremariam T, Husseiny MI, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother. 2008;52:1573–6.PubMedCrossRef Ibrahim AS, Gebremariam T, Husseiny MI, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother. 2008;52:1573–6.PubMedCrossRef
53.
go back to reference MacCallum DM, Odds FC. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses. 2005;48:151–61.PubMedCrossRef MacCallum DM, Odds FC. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses. 2005;48:151–61.PubMedCrossRef
54.
go back to reference • Lionakis MS, Lim JK, Lee CC, Murphy PM. Organ-specific innate immune responses in a mouse model of invasive candidiasis. J Innate Immun. 2011;3:180–99. Recent murine model that demonstrated differences in the temporal and spatial accumulation of leukocytes within different organs following intravenous challenge of mice with C. albicans.PubMedCrossRef • Lionakis MS, Lim JK, Lee CC, Murphy PM. Organ-specific innate immune responses in a mouse model of invasive candidiasis. J Innate Immun. 2011;3:180–99. Recent murine model that demonstrated differences in the temporal and spatial accumulation of leukocytes within different organs following intravenous challenge of mice with C. albicans.PubMedCrossRef
55.
go back to reference Liu Y, Filler SG. Candida albicans Als3, a multifunctional adhesin and invasin. Eukaryot Cell. 2011;10:168–73.PubMedCrossRef Liu Y, Filler SG. Candida albicans Als3, a multifunctional adhesin and invasin. Eukaryot Cell. 2011;10:168–73.PubMedCrossRef
56.
go back to reference Liu Y, Mittal R, Solis NV, et al. Mechanisms of Candida albicans trafficking to the brain. PLoS Pathog. 2011;7:e1002305.PubMedCrossRef Liu Y, Mittal R, Solis NV, et al. Mechanisms of Candida albicans trafficking to the brain. PLoS Pathog. 2011;7:e1002305.PubMedCrossRef
57.
go back to reference Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163–71.PubMedCrossRef Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163–71.PubMedCrossRef
58.
go back to reference Petraitiene R, Petraitis V, Hope WW, et al. Cerebrospinal fluid and plasma (1–>3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis. Antimicrob Agents Chemother. 2008;52:4121–9.PubMedCrossRef Petraitiene R, Petraitis V, Hope WW, et al. Cerebrospinal fluid and plasma (1–>3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis. Antimicrob Agents Chemother. 2008;52:4121–9.PubMedCrossRef
59.
go back to reference Spellberg B, Ibrahim AS, Edwards Jr JE, Filler SG. Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis. 2005;192:336–43.PubMedCrossRef Spellberg B, Ibrahim AS, Edwards Jr JE, Filler SG. Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis. 2005;192:336–43.PubMedCrossRef
60.
go back to reference Lionakis MS, Fischer BG, Lim JK, et al. Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog. 2012;8:e1002865.PubMedCrossRef Lionakis MS, Fischer BG, Lim JK, et al. Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog. 2012;8:e1002865.PubMedCrossRef
61.
go back to reference Ostrosky-Zeichner L, Paetznick VL, Rodriguez J, et al. Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. Antimicrob Agents Chemother. 2009;53:1639–41.PubMedCrossRef Ostrosky-Zeichner L, Paetznick VL, Rodriguez J, et al. Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. Antimicrob Agents Chemother. 2009;53:1639–41.PubMedCrossRef
62.
go back to reference Salas V, Pastor FJ, Calvo E, et al. Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1–>3)-beta-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy. Antimicrob Agents Chemother. 2011;55:4985–9.PubMedCrossRef Salas V, Pastor FJ, Calvo E, et al. Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1–>3)-beta-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy. Antimicrob Agents Chemother. 2011;55:4985–9.PubMedCrossRef
63.
go back to reference Spreghini E, Orlando F, Tavanti A, et al. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother. 2012;67:2195–202.PubMedCrossRef Spreghini E, Orlando F, Tavanti A, et al. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother. 2012;67:2195–202.PubMedCrossRef
64.
go back to reference Brzankalski GE, Najvar LK, Wiederhold NP, et al. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J Antimicrob Chemother. 2008;62:1094–100.PubMedCrossRef Brzankalski GE, Najvar LK, Wiederhold NP, et al. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J Antimicrob Chemother. 2008;62:1094–100.PubMedCrossRef
65.
go back to reference Graybill JR, Bocanegra R, Luther M, et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother. 1997;41:1937–9.PubMed Graybill JR, Bocanegra R, Luther M, et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother. 1997;41:1937–9.PubMed
66.
go back to reference Graybill JR, Najvar LK, Luther MF, Fothergill AW. Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother. 1997;41:1775–7.PubMed Graybill JR, Najvar LK, Luther MF, Fothergill AW. Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother. 1997;41:1775–7.PubMed
67.
go back to reference Wiederhold NP, Najvar LK, Bocanegra R, et al. Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis. Clin Microbiol Infect. 2012;18:E20–3.PubMedCrossRef Wiederhold NP, Najvar LK, Bocanegra R, et al. Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis. Clin Microbiol Infect. 2012;18:E20–3.PubMedCrossRef
68.
go back to reference Warn PA, Sharp A, Parmar A, et al. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother. 2009;53:3453–61.PubMedCrossRef Warn PA, Sharp A, Parmar A, et al. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother. 2009;53:3453–61.PubMedCrossRef
69.
go back to reference Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020–9.PubMedCrossRef Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020–9.PubMedCrossRef
70.
go back to reference Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am. 2006;20:679–97.PubMedCrossRef Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am. 2006;20:679–97.PubMedCrossRef
71.
go back to reference Hope WW, Drusano GL. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect. 2009;15:602–12.PubMedCrossRef Hope WW, Drusano GL. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect. 2009;15:602–12.PubMedCrossRef
72.
go back to reference Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676–84.PubMedCrossRef Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676–84.PubMedCrossRef
73.
go back to reference Najvar LK, Bocanegra R, Wiederhold NP, et al. Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice. Clin Microbiol Infect. 2008;14:595–600.PubMedCrossRef Najvar LK, Bocanegra R, Wiederhold NP, et al. Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice. Clin Microbiol Infect. 2008;14:595–600.PubMedCrossRef
74.
go back to reference Wiederhold NP, Najvar LK, Bocanegra RA, et al. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother. 2011;55:3254–60.PubMedCrossRef Wiederhold NP, Najvar LK, Bocanegra RA, et al. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother. 2011;55:3254–60.PubMedCrossRef
75.
go back to reference Ben-Ami R, Garcia-Effron G, Lewis RE, et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis. 2011;204:626–35.PubMedCrossRef Ben-Ami R, Garcia-Effron G, Lewis RE, et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis. 2011;204:626–35.PubMedCrossRef
76.
go back to reference Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: an update. Eukaryot Cell. 2005;4:633–8.PubMedCrossRef Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: an update. Eukaryot Cell. 2005;4:633–8.PubMedCrossRef
77.
go back to reference Hawser SP, Baillie GS, Douglas LJ. Production of extracellular matrix by Candida albicans biofilms. J Med Microbiol. 1998;47:253–6.PubMedCrossRef Hawser SP, Baillie GS, Douglas LJ. Production of extracellular matrix by Candida albicans biofilms. J Med Microbiol. 1998;47:253–6.PubMedCrossRef
78.
go back to reference Andes D, Nett J, Oschel P, et al. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun. 2004;72:6023–31.PubMedCrossRef Andes D, Nett J, Oschel P, et al. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun. 2004;72:6023–31.PubMedCrossRef
79.
go back to reference Robbins N, Uppuluri P, Nett J, et al. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 2011;7:e1002257.PubMedCrossRef Robbins N, Uppuluri P, Nett J, et al. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 2011;7:e1002257.PubMedCrossRef
80.
go back to reference Uppuluri P, Nett J, Heitman J, Andes D. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother. 2008;52:1127–32.PubMedCrossRef Uppuluri P, Nett J, Heitman J, Andes D. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother. 2008;52:1127–32.PubMedCrossRef
81.
go back to reference Nobile CJ, Fox EP, Nett JE, et al. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell. 2012;148:126–38.PubMedCrossRef Nobile CJ, Fox EP, Nett JE, et al. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell. 2012;148:126–38.PubMedCrossRef
82.
go back to reference Schinabeck MK, Long LA, Hossain MA, et al. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother. 2004;48:1727–32.PubMedCrossRef Schinabeck MK, Long LA, Hossain MA, et al. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother. 2004;48:1727–32.PubMedCrossRef
83.
go back to reference Chandra J, Long L, Ghannoum MA, Mukherjee PK. A rabbit model for evaluation of catheter-associated fungal biofilms. Virulence. 2011;2:466–74.PubMedCrossRef Chandra J, Long L, Ghannoum MA, Mukherjee PK. A rabbit model for evaluation of catheter-associated fungal biofilms. Virulence. 2011;2:466–74.PubMedCrossRef
84.
go back to reference Savage DC, Dubos RJ. Localization of indigenous yeast in the murine stomach. J Bacteriol. 1967;94:1811–6.PubMed Savage DC, Dubos RJ. Localization of indigenous yeast in the murine stomach. J Bacteriol. 1967;94:1811–6.PubMed
85.
go back to reference Kamai Y, Kubota M, Hosokawa T, et al. New model of oropharyngeal candidiasis in mice. Antimicrob Agents Chemother. 2001;45:3195–7.PubMedCrossRef Kamai Y, Kubota M, Hosokawa T, et al. New model of oropharyngeal candidiasis in mice. Antimicrob Agents Chemother. 2001;45:3195–7.PubMedCrossRef
86.
go back to reference Spellberg BJ, Ibrahim AS, Avanesian V, et al. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis. 2006;194:256–60.PubMedCrossRef Spellberg BJ, Ibrahim AS, Avanesian V, et al. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis. 2006;194:256–60.PubMedCrossRef
87.
go back to reference Chiang LY, Sheppard DC, Bruno VM, et al. Candida albicans protein kinase CK2 governs virulence during oropharyngeal candidiasis. Cell Microbiol. 2007;9:233–45.PubMedCrossRef Chiang LY, Sheppard DC, Bruno VM, et al. Candida albicans protein kinase CK2 governs virulence during oropharyngeal candidiasis. Cell Microbiol. 2007;9:233–45.PubMedCrossRef
88.
go back to reference Zhu W, Phan QT, Boontheung P, et al. EGFR and HER2 receptor kinase signaling mediate epithelial cell invasion by Candida albicans during oropharyngeal infection. Proc Natl Acad Sci U S A. 2012;109:14194–9.PubMedCrossRef Zhu W, Phan QT, Boontheung P, et al. EGFR and HER2 receptor kinase signaling mediate epithelial cell invasion by Candida albicans during oropharyngeal infection. Proc Natl Acad Sci U S A. 2012;109:14194–9.PubMedCrossRef
89.
go back to reference Nett JE, Marchillo K, Spiegel CA, Andes DR. Development and validation of an in vivo Candida albicans biofilm denture model. Infect Immun. 2010;78:3650–9.PubMedCrossRef Nett JE, Marchillo K, Spiegel CA, Andes DR. Development and validation of an in vivo Candida albicans biofilm denture model. Infect Immun. 2010;78:3650–9.PubMedCrossRef
90.
go back to reference • Johnson CC, Yu A, Lee H, et al. Development of a contemporary animal model of Candida albicans-associated denture stomatitis using a novel intraoral denture system. Infect Immun. 2012;80:1736–43. New model of dental stomatitis in rats in which the development of the C. albicans biofilm on the removable prosthetic and tissue inflammation closely mimic that observed in humans.PubMedCrossRef • Johnson CC, Yu A, Lee H, et al. Development of a contemporary animal model of Candida albicans-associated denture stomatitis using a novel intraoral denture system. Infect Immun. 2012;80:1736–43. New model of dental stomatitis in rats in which the development of the C. albicans biofilm on the removable prosthetic and tissue inflammation closely mimic that observed in humans.PubMedCrossRef
92.
go back to reference Yano J, Noverr MC, Fidel Jr PL. Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins. Cytokine. 2012;58:118–28.PubMedCrossRef Yano J, Noverr MC, Fidel Jr PL. Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins. Cytokine. 2012;58:118–28.PubMedCrossRef
93.
go back to reference Yamaguchi N, Sonoyama K, Kikuchi H, et al. Gastric colonization of Candida albicans differs in mice fed commercial and purified diets. J Nutr. 2005;135:109–15.PubMed Yamaguchi N, Sonoyama K, Kikuchi H, et al. Gastric colonization of Candida albicans differs in mice fed commercial and purified diets. J Nutr. 2005;135:109–15.PubMed
94.
go back to reference Hardison SE, Herrera G, Young ML, et al. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J Immunol. 2012;189:4060–8.PubMedCrossRef Hardison SE, Herrera G, Young ML, et al. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J Immunol. 2012;189:4060–8.PubMedCrossRef
95.
go back to reference Hole CR, Wormley Jr FL. Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol. 2012;3:291.PubMed Hole CR, Wormley Jr FL. Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol. 2012;3:291.PubMed
96.
go back to reference Lortholary O, Improvisi L, Rayhane N, et al. Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection. Infect Immun. 1999;67:6314–20.PubMed Lortholary O, Improvisi L, Rayhane N, et al. Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection. Infect Immun. 1999;67:6314–20.PubMed
97.
go back to reference Lortholary O, Nicolas M, Soreda S, et al. Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. J Antimicrob Chemother. 1999;43:817–24.PubMedCrossRef Lortholary O, Nicolas M, Soreda S, et al. Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. J Antimicrob Chemother. 1999;43:817–24.PubMedCrossRef
98.
go back to reference Diamond DM, Bauer M, Daniel BE, et al. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother. 1998;42:528–33.PubMed Diamond DM, Bauer M, Daniel BE, et al. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother. 1998;42:528–33.PubMed
99.
go back to reference Ding JC, Bauer M, Diamond DM, et al. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother. 1997;41:1589–93.PubMed Ding JC, Bauer M, Diamond DM, et al. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother. 1997;41:1589–93.PubMed
100.
go back to reference Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291–322.PubMedCrossRef Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291–322.PubMedCrossRef
101.
go back to reference Kirkpatrick WR, Najvar LK, Bocanegra R, et al. New guinea pig model of Cryptococcal meningitis. Antimicrob Agents Chemother. 2007;51:3011–3.PubMedCrossRef Kirkpatrick WR, Najvar LK, Bocanegra R, et al. New guinea pig model of Cryptococcal meningitis. Antimicrob Agents Chemother. 2007;51:3011–3.PubMedCrossRef
102.
go back to reference Carroll SF, Guillot L, Qureshi ST. Mammalian model hosts of cryptococcal infection. Comp Med. 2007;57:9–17.PubMed Carroll SF, Guillot L, Qureshi ST. Mammalian model hosts of cryptococcal infection. Comp Med. 2007;57:9–17.PubMed
103.
go back to reference Odom A, Del Poeta M, Perfect J, Heitman J. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother. 1997;41:156–61.PubMed Odom A, Del Poeta M, Perfect J, Heitman J. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother. 1997;41:156–61.PubMed
104.
go back to reference Goldman D, Lee SC, Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun. 1994;62:4755–61.PubMed Goldman D, Lee SC, Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun. 1994;62:4755–61.PubMed
105.
go back to reference Graybill JR, Ahrens J, Nealon T, Paque R. Pulmonary cryptococcosis in the rat. Am Rev Respir Dis. 1983;127:636–40.PubMed Graybill JR, Ahrens J, Nealon T, Paque R. Pulmonary cryptococcosis in the rat. Am Rev Respir Dis. 1983;127:636–40.PubMed
106.
go back to reference Capilla J, Maffei CM, Clemons KV, et al. Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice. Med Mycol. 2006;44:601–10.PubMedCrossRef Capilla J, Maffei CM, Clemons KV, et al. Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice. Med Mycol. 2006;44:601–10.PubMedCrossRef
107.
go back to reference Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol. 2001;39:155–68.PubMed Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol. 2001;39:155–68.PubMed
108.
go back to reference Thompson 3rd GR, Wiederhold NP, Najvar LK, et al. A murine model of Cryptococcus gattii meningoencephalitis. J Antimicrob Chemother. 2012;67:1432–8.PubMedCrossRef Thompson 3rd GR, Wiederhold NP, Najvar LK, et al. A murine model of Cryptococcus gattii meningoencephalitis. J Antimicrob Chemother. 2012;67:1432–8.PubMedCrossRef
109.
go back to reference Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis. 1995;20:611–6.PubMedCrossRef Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis. 1995;20:611–6.PubMedCrossRef
110.
go back to reference Hospenthal DR, Bennett JE. Persistence of cryptococcomas on neuroimaging. Clin Infect Dis. 2000;31:1303–6.PubMedCrossRef Hospenthal DR, Bennett JE. Persistence of cryptococcomas on neuroimaging. Clin Infect Dis. 2000;31:1303–6.PubMedCrossRef
111.
go back to reference • Chamilos G, Lionakis MS, Lewis RE, Kontoyiannis DP. Role of mini-host models in the study of medically important fungi. Lancet Infect Dis. 2007;7:42–55. Excellent review of invertebrate host models of invasive fungal infections.PubMedCrossRef • Chamilos G, Lionakis MS, Lewis RE, Kontoyiannis DP. Role of mini-host models in the study of medically important fungi. Lancet Infect Dis. 2007;7:42–55. Excellent review of invertebrate host models of invasive fungal infections.PubMedCrossRef
112.
go back to reference Pukkila-Worley R, Holson E, Wagner F, Mylonakis E. Antifungal drug discovery through the study of invertebrate model hosts. Curr Med Chem. 2009;16:1588–95.PubMedCrossRef Pukkila-Worley R, Holson E, Wagner F, Mylonakis E. Antifungal drug discovery through the study of invertebrate model hosts. Curr Med Chem. 2009;16:1588–95.PubMedCrossRef
113.
go back to reference Lionakis MS, Lewis RE, May GS, et al. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis. 2005;191:1188–95.PubMedCrossRef Lionakis MS, Lewis RE, May GS, et al. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis. 2005;191:1188–95.PubMedCrossRef
114.
go back to reference Cowen LE, Singh SD, Kohler JR, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A. 2009;106:2818–23.PubMedCrossRef Cowen LE, Singh SD, Kohler JR, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A. 2009;106:2818–23.PubMedCrossRef
115.
go back to reference Tzou P, Ohresser S, Ferrandon D, et al. Tissue-specific inducible expression of antimicrobial peptide genes in Drosophila surface epithelia. Immunity. 2000;13:737–48.PubMedCrossRef Tzou P, Ohresser S, Ferrandon D, et al. Tissue-specific inducible expression of antimicrobial peptide genes in Drosophila surface epithelia. Immunity. 2000;13:737–48.PubMedCrossRef
116.
go back to reference Brennan CA, Anderson KV. Drosophila: the genetics of innate immune recognition and response. Annu Rev Immunol. 2004;22:457–83.PubMedCrossRef Brennan CA, Anderson KV. Drosophila: the genetics of innate immune recognition and response. Annu Rev Immunol. 2004;22:457–83.PubMedCrossRef
117.
go back to reference Ha EM, Oh CT, Bae YS, Lee WJ. A direct role for dual oxidase in Drosophila gut immunity. Science. 2005;310:847–50.PubMedCrossRef Ha EM, Oh CT, Bae YS, Lee WJ. A direct role for dual oxidase in Drosophila gut immunity. Science. 2005;310:847–50.PubMedCrossRef
118.
go back to reference Chamilos G, Lionakis MS, Lewis RE, et al. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis. 2006;193:1014–22.PubMedCrossRef Chamilos G, Lionakis MS, Lewis RE, et al. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis. 2006;193:1014–22.PubMedCrossRef
119.
go back to reference Lamaris GA, Chamilos G, Lewis RE, Kontoyiannis DP. Virulence studies of Scedosporium and Fusarium species in Drosophila melanogaster. J Infect Dis. 2007;196:1860–4.PubMedCrossRef Lamaris GA, Chamilos G, Lewis RE, Kontoyiannis DP. Virulence studies of Scedosporium and Fusarium species in Drosophila melanogaster. J Infect Dis. 2007;196:1860–4.PubMedCrossRef
120.
go back to reference Lionakis MS. Drosophila and Galleria insect model hosts: new tools for the study of fungal virulence, pharmacology and immunology. Virulence. 2011;2:521–7.PubMedCrossRef Lionakis MS. Drosophila and Galleria insect model hosts: new tools for the study of fungal virulence, pharmacology and immunology. Virulence. 2011;2:521–7.PubMedCrossRef
121.
go back to reference Cronin SJ, Nehme NT, Limmer S, et al. Genome-wide RNAi screen identifies genes involved in intestinal pathogenic bacterial infection. Science. 2009;325:340–3.PubMedCrossRef Cronin SJ, Nehme NT, Limmer S, et al. Genome-wide RNAi screen identifies genes involved in intestinal pathogenic bacterial infection. Science. 2009;325:340–3.PubMedCrossRef
122.
go back to reference Mylonakis E, Casadevall A, Ausubel FM. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog. 2007;3:e101.PubMedCrossRef Mylonakis E, Casadevall A, Ausubel FM. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog. 2007;3:e101.PubMedCrossRef
123.
go back to reference Mylonakis E, Moreno R, El Khoury JB, et al. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun. 2005;73:3842–50.PubMedCrossRef Mylonakis E, Moreno R, El Khoury JB, et al. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun. 2005;73:3842–50.PubMedCrossRef
124.
go back to reference Vogel H, Altincicek B, Glockner G, Vilcinskas A. A comprehensive transcriptome and immune-gene repertoire of the lepidopteran model host Galleria mellonella. BMC Genomics. 2011;12:308.PubMedCrossRef Vogel H, Altincicek B, Glockner G, Vilcinskas A. A comprehensive transcriptome and immune-gene repertoire of the lepidopteran model host Galleria mellonella. BMC Genomics. 2011;12:308.PubMedCrossRef
125.
go back to reference London R, Orozco BS, Mylonakis E. The pursuit of cryptococcal pathogenesis: heterologous hosts and the study of cryptococcal host-pathogen interactions. FEMS Yeast Res. 2006;6:567–73.PubMedCrossRef London R, Orozco BS, Mylonakis E. The pursuit of cryptococcal pathogenesis: heterologous hosts and the study of cryptococcal host-pathogen interactions. FEMS Yeast Res. 2006;6:567–73.PubMedCrossRef
Metadata
Title
Animal Models In Mycology: What Have We Learned Over The Past 30 Years
Authors
William R. Kirkpatrick
Nathan P. Wiederhold
Laura K. Najvar
Thomas F. Patterson
Publication date
01-03-2013
Publisher
Current Science Inc.
Published in
Current Fungal Infection Reports / Issue 1/2013
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-012-0126-6

Other articles of this Issue 1/2013

Current Fungal Infection Reports 1/2013 Go to the issue

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

EUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

1–3 β-D-glucan: From Diagnosis to Prognosis

Current Management of Fungal Infections (Luis Ostrosky-Zeichner, Section Editor)

How I Treat Histoplasmosis

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Penicillium marneffei Infection in Immunocompromised Host